Biognosys Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 58
Employees
  • Latest Deal Type
  • Series G
  • Latest Deal Amount
  • $5.76M
Latest Deal Amount
  • Investors
  • 6

Biognosys General Information

Description

Developer of next-generation proteomics tools designed to transform life science research for highly multiplexed protein quantification. The company's proteomics tools are based on high-resolution mass spectrometry, combined with a novel parallel signal processing approach that decodes the proteome and equips researchers from all fields with a deep view of protein expression in cells, tissues, or body fluids, thus enabling researchers and scientists to access valuable information on their protein analysis needs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • Wagistrasse 21
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00

Biognosys Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Biognosys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC (Series G) 08-Aug-2019 $5.76M 0000 000.00 Completed Generating Revenue
10. Secondary Transaction - Private 000.00 Completed Generating Revenue
9. Later Stage VC (Series C) 12-Jul-2017 000 000.00 Completed Generating Revenue
8. Later Stage VC 23-Dec-2015 00.000 000.00 000.00 Completed Generating Revenue
7. Later Stage VC 22-May-2015 00.000 00.000 000.00 Completed Generating Revenue
6. Accelerator/Incubator 00.000 Completed Startup
5. Early Stage VC 07-Dec-2012 00.00 00.000 000.00 Completed Startup
4. Grant 21-Feb-2012 00.000 00.000 Completed Startup
3. Early Stage VC (Series A) 31-Oct-2011 $2.87M $2.87M 000.00 Completed Startup
2. Accelerator/Incubator 01-Jan-2009 $26.4K Completed Startup
To view Biognosys’s complete valuation and funding history, request access »

Biognosys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series G 0,000,000 00.00 00.00 00 00.00 00.000
Series F 0,000,000 00.00 00.00 00 00.00 00.000
Series E 0,000,000 00.00 00.00 00 00.00 00.000
Series D 3,603,488 $0.48 $0.48 1x $0.48 6.44%
Preference 9,634,868 $0.43 $0.43 1x $0.43 17.23%
To view Biognosys’s complete cap table history, request access »

Biognosys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of next-generation proteomics tools designed to transform life science research for highly multiplexed protein
Discovery Tools (Healthcare)
Schlieren, Switzerland
58 As of 2021
0000
00.00 0000-00-00
00000000000 0000

00000000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
0000000000000
Munich, Germany
00 As of 0000
00.000
0000000000 00.000

00000000

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
000000000 00000 (0000000000)
Montreal, Canada
000 As of 0000
0000 0000-00-00
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biognosys Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PreOmics Venture Capital-Backed Munich, Germany 00 00.000 0000000000 00.000
000000000 Private Equity-Backed Montreal, Canada 000 000000000000
000000000 Private Equity-Backed Boulder, CO 000 00.000 000000000 00.000
000000 00000000000 Venture Capital-Backed Seattle, WA 0 00.00 0000000000 0 00.00
To view Biognosys’s complete competitors history, request access »

Biognosys Executive Team (11)

Name Title Board Seat Contact Info
Oliver Rinner Ph.D Co-Founder, Chief Executive Officer & Board Member
Lidia Novak Chief Financial Officer
Karel Novy Ph.D Chief Operating Officer
Lukas Reiter Ph.D Chief Technology Officer
Kristina Beeler Chief Business Officer
You’re viewing 5 of 11 executive team members. Get the full list »

Biognosys Board Members (14)

Name Representing Role Since
Christian Wolfrum Ph.D Self Board Member 000 0000
Dean Haworth PM Equity Partner Board Member 000 0000
Manuel Peitsch Biognosys Board Member 000 0000
Michael Lee Ph.D Syngenta Group Ventures Board Member 000 0000
Oliver Rinner Ph.D Biognosys Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Biognosys Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biognosys Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
PM Equity Partner Corporate Venture Capital Minority 000 0000 000000 0
Syngenta Group Ventures Corporate Venture Capital Minority 000 0000 000000 0
TVM Capital Life Science Venture Capital Minority 000 0000 000000 0
Zürcher Kantonalbank Corporation Minority 000 0000 000000 0
Venture Kick Accelerator/Incubator Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »